ZVRA

Zevra Therapeutics, Inc.

Fundamental data last updated:November 14, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

United States

Next Earnings Date

03/08/2027

Business Summary

ZVRA's business model revolves around innovative biotechnology solutions, focusing on niche therapeutic areas. By developing proprietary drugs, they generate cash through sales and strategic partnerships. Their competitive moat lies in their specialized expertise and strong R&D capabilities, which create high barriers to entry. This focus on innovation and exclusivity helps lock in customers and sustain long-term growth.

 


Analyze ZVRA on TradingView

VALUATION

P/E

9.31

Market Cap ($M USD)

$707.85M

Forward P/E

9.60

PEG

-13.91

PRICE TO SALES

4.79

PRICE TO BOOK

2.96

EV / EBITDA

7.03

5-Year Average P/E

Free Cash Flow Yield

5.41%

DCF Value

$-35.80

Graham Number

$10.90

Price to FCF

18.49

EV to FCF

15.33

Earnings Yield

11.02%

FCF Yield

5.41%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.31

Next Year EPS Growth Estimate

$1.24

Next Year Revenue Growth Estimate

$153.54M

Return on Equity (ROE)

38.19%

FREE CASH FLOW

Operating Margin

31.47%

Debt-to-Equity

0.01

Piotroski F-Score

6

Altman Z-Score

5.98

Return on Invested Capital (ROIC)

14.78%

Current Ratio

5.46

Quick Ratio

5.38

Net Debt to EBITDA

-1.45

Interest Coverage

12.71

Gross Profit margin

94.98%

FCF PER SHARE

$0.64

REVENUE PER SHARE

$2.49

Analyze ZVRA on TradingView

Gainseekers Quantitative Analysis

Summary

ZVRA Zevra Therapeutics, Inc. presents a perplexing valuation scenario. Despite a Forward P/E of 9.60, suggesting potential undervaluation, the DCF Value is alarmingly negative, indicating market skepticism about future cash flows. The Earnings Yield of 11.02% is attractive, yet the Graham Number suggests the stock is trading above its intrinsic value. However, with an Altman Z-score of 5.98, the company appears financially stable, reducing bankruptcy risk. The market may be mispricing this stock, but caution is warranted given the DCF concerns.

AI Exposure / Tech Reliance

In the biotechnology sector, ZVRA is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with technological shifts, providing resilience against obsolescence. As AI continues to transform healthcare, ZVRA's adaptability could enhance its competitive edge.

The Bull Case

For value or GARP investors, ZVRA offers compelling reasons to buy. With a robust ROIC of 14.78%, the company demonstrates efficient capital allocation, translating into strong returns. A Piotroski F-Score of 6 indicates solid financial health, while an impressive operating margin of 31.47% showcases pricing power. The FCF Yield, although modest, suggests potential for cash flow growth, making it an attractive prospect for those seeking undervalued opportunities with growth potential.

The Bear Case

Despite its strengths, ZVRA faces significant structural risks. The Price/Sales ratio of 4.79 and Price/Book of 2.96 suggest the stock may be overvalued relative to its peers. The negative DCF Value raises red flags about future profitability, and the stock's proximity to its 52-week high indicates potential overextension. Investors should be wary of these valuation concerns, as they could signal limited upside potential.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$25.75

Institutional Ownership %

1-Year Beta

0.99

Insider Buying % (6 Mo)

Distance to 52-Week High

26.17%

Distance to 52-Week Low

32.80%

EARNINGS SURPRISE %

64.97%

50-DAY SMA

$11.07

200-DAY SMA

$10.79

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.